Merck KGaA offloads failed MEK programme to startup Day OneUS biotech Day One has taken ownership of a cancer drug that has been languishing in Merck KGaA’s Share XMerck KGaA offloads failed MEK programme to startup Day Onehttps://pharmaphorum.com/news/merck-kgaa-offloads-failed-mek-programme-to-startup-day-one/
Lilly adds to pain pipeline with Asahi Kasei licensing dealUS drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has Share XLilly adds to pain pipeline with Asahi Kasei licensing dealhttps://pharmaphorum.com/news/lilly-adds-to-pain-pipeline-with-asahi-kasei-licensing-deal/
Bayer joins the COVID-19 vaccine push, backing CureVac shotShortly after launching large-scale trials of its COVID-19 vaccine candidate, CureVac has the partner it will need to Share XBayer joins the COVID-19 vaccine push, backing CureVac shothttps://pharmaphorum.com/news/bayer-joins-the-covid-19-vaccine-push-backing-curevacs-shot/
Amgen hands off leprosy, TB candidate to Australian non-profitAmgen has decided that a drug for leprosy and tuberculosis it inherited as part of its acquisition of Share XAmgen hands off leprosy, TB candidate to Australian non-profithttps://pharmaphorum.com/news/amgen-hands-off-leprosy-tb-candidate-to-australian-non-profit/
Merck cuts $1bn deal with Janux for cancer T-cell therapiesIn a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Share XMerck cuts $1bn deal with Janux for cancer T-cell therapieshttps://pharmaphorum.com/news/merck-cuts-1bn-deal-with-janux-for-cancer-t-cell-therapies/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
Biogen teams up with gene-editing startup Scribe on ALS programmeScribe Therapeutics, a start-up focusing on gene-editing using CRISPR/Cas9, has burst onto the biotech scene with a $415 Share XBiogen teams up with gene-editing startup Scribe on ALS programmehttps://pharmaphorum.com/news/biogen-teams-up-with-gene-editing-startup-scribe-on-als-programme/
AZ buys oral PCSK9 cholesterol drug from Dogma TherapeuticsAstraZeneca has bought rights to an orally-active drug that inhibits PCSK9, offering a patient-friendly alternative to current cholesterol-lowering Share XAZ buys oral PCSK9 cholesterol drug from Dogma Therapeuticshttps://pharmaphorum.com/news/az-buys-oral-pcsk9-cholesterol-drug-from-dogma-therapeutics/
Exelixis doubles down on ADCs for cancer with NBE, Catalent dealsExelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug Share XExelixis doubles down on ADCs for cancer with NBE, Catalent dealshttps://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/
